TFRC and acute myeloid leukemia: suggested that CD71 is a invariably marker and highly expressed in different subtypes of leukemia cells based on which they designed a biomimetic carrier for precision delivery of AsIII, As@Fn nanomedicine, to bind to HL-60 AML leukemia cells characterized by CD71 (119).